Healthcare >> Analyst Interviews >> June 13, 2011

Growth Catalysts In The Orphan Drug Space – Kimberly Lee – Global Hunter Securities, Llc

Dr. Kimberly Lee, D.O., is a Managing Director and Senior Analyst at Global Hunter Securities, LLC, where she focuses on the health care sector. Dr. Lee was most recently a Senior Research Analyst covering biotechnology at Wedbush Securities, identifying and recommending investment ideas to institutional clients, in addition to developing a widely followed annual industry outlook report. While at Wedbush, Dr. Lee received a four-star rating from StarMine for stock picking and performance. Previously she was a Senior Research Analyst at Pacific Growth Equities, LLC, which was acquired by Wedbush, and a Senior Research Associate covering biotechnology at Jefferies & Company, Inc., and Stephens Inc. Dr. Lee earned her Doctor of Osteopathathic Medicine from Kirksville College of Osteopathic Medicine and a Bachelor of Science in biological sciences from Stanford University. She received postdoctoral training in obstetrics and gynecology at Brookdale University Hospital and Medical Center, and Allegheny General Hospital. Profile
TWST: Where do you focus your attention in the biotech space these days?

Dr. Lee: My focus is on the small- and mid-cap stocks, and more specifically on companies that are developing drugs in orphan